2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 20:22, 2 December 2023
, 2 December 2023→Clinical Trials
| Line 351: | Line 351: | ||
| | | | ||
* Supplementing hypertension patients with 800 mg of oral NMN per day for six weeks significantly lowers their blood pressure. | * Supplementing hypertension patients with 800 mg of oral NMN per day for six weeks significantly lowers their blood pressure. | ||
* Hypertension patients display significantly lower blood cell NAD+ levels, and taking NMN increases their blood cell NAD+ levels by ~43% | * Hypertension patients display significantly lower blood cell NAD+ levels, and taking NMN increases their blood cell NAD+ levels by ~43%. | ||
* Adults with hypertension have cells lining blood vessels — endothelial cells — with elevated concentrations of the NAD+ consuming enzyme CD38, which partially explains their lower NAD+ levels. | * Adults with hypertension have cells lining blood vessels — endothelial cells — with elevated concentrations of the NAD+ consuming enzyme CD38, which partially explains their lower NAD+ levels. | ||
|} | |} | ||